These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 16940077)

  • 1. Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection.
    Lau WK; Mercer D; Itani KM; Nicolau DP; Kuti JL; Mansfield D; Dana A
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3556-61. PubMed ID: 16940077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
    Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
    Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection.
    Li C; Kuti JL; Nightingale CH; Mansfield DL; Dana A; Nicolau DP
    J Antimicrob Chemother; 2005 Aug; 56(2):388-95. PubMed ID: 16002420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
    Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
    Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
    Cotrina-Luque J; Gil-Navarro MV; Acosta-García H; Alfaro-Lara ER; Luque-Márquez R; Beltrán-García M; Bautista-Paloma FJ
    Int J Clin Pharm; 2016 Feb; 38(1):70-9. PubMed ID: 26474861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital.
    Grant EM; Kuti JL; Nicolau DP; Nightingale C; Quintiliani R
    Pharmacotherapy; 2002 Apr; 22(4):471-83. PubMed ID: 11939682
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinafloxacin versus piperacillin-tazobactam in treatment of patients with severe skin and soft tissue infections.
    Siami G; Christou N; Eiseman I; Tack KJ;
    Antimicrob Agents Chemother; 2001 Feb; 45(2):525-31. PubMed ID: 11158750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam.
    Kim MK; Capitano B; Mattoes HM; Xuan D; Quintiliani R; Nightingale CH; Nicolau DP
    Pharmacotherapy; 2002 May; 22(5):569-77. PubMed ID: 12013355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
    Graham DR; Lucasti C; Malafaia O; Nichols RL; Holtom P; Perez NQ; McAdams A; Woods GL; Ceesay TP; Gesser R
    Clin Infect Dis; 2002 Jun; 34(11):1460-8. PubMed ID: 12015692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
    Dela Pena AS; Asperger W; Köckerling F; Raz R; Kafka R; Warren B; Shivaprakash M; Vrijens F; Giezek H; DiNubile MJ; Chan CY;
    J Gastrointest Surg; 2006 Apr; 10(4):567-74. PubMed ID: 16627223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized multicenter trial of piperacillin/tazobactam versus imipenem/cilastatin in the treatment of severe intra-abdominal infections. Swedish Study Group.
    Eklund AE; Nord CE
    J Antimicrob Chemother; 1993 Jan; 31 Suppl A():79-85. PubMed ID: 8383657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Piperacillin/tazobactam therapy for diabetic foot infection.
    Zeillemaker AM; Veldkamp KE; van Kraaij MG; Hoekstra JB; Hoynck van Papendrecht AA; Diepersloot RJ
    Foot Ankle Int; 1998 Mar; 19(3):169-72. PubMed ID: 9542990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections.
    Brismar B; Malmborg AS; Tunevall G; Wretlind B; Bergman L; Mentzing LO; Nyström PO; Kihlström E; Bäckstrand B; Skau T
    Antimicrob Agents Chemother; 1992 Dec; 36(12):2766-73. PubMed ID: 1336347
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
    Lodise TP; Lomaestro B; Drusano GL
    Clin Infect Dis; 2007 Feb; 44(3):357-63. PubMed ID: 17205441
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients.
    Shea KM; Cheatham SC; Smith DW; Wack MF; Sowinski KM; Kays MB
    Ann Pharmacother; 2009 Nov; 43(11):1747-54. PubMed ID: 19809009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized controlled clinical trial on piperacillin/tazobactam versus ticarcillin/clavulanic acid for the treatment of bacterial infections.
    Hou F; Li J; Gao L; Chen Y
    Chin Med J (Engl); 1998 Nov; 111(11):1039-43. PubMed ID: 11189212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of the North American trial of piperacillin/tazobactam compared with clindamycin and gentamicin in the treatment of severe intra-abdominal infections. Investigators of the Piperacillin/Tazobactam Intra-abdominal Infection Study Group.
    Eur J Surg Suppl; 1994; (573):61-6. PubMed ID: 7524798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Piperacillin-tazobactam pharmacokinetics in patients with intraabdominal infections.
    Jhee SS; Kern JW; Burm JP; Yellin AE; Gill MA
    Pharmacotherapy; 1995; 15(4):472-8. PubMed ID: 7479200
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
    Roy S; Higareda I; Angel-Muller E; Ismail M; Hague C; Adeyi B; Woods GL; Teppler H;
    Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacoeconomics of continuous versus intermittent infusion of piperacillin-tazobactam for the treatment of complicated intraabdominal infection.
    DeRyke CA; Kuti JL; Mansfield D; Dana A; Nicolau DP
    Am J Health Syst Pharm; 2006 Apr; 63(8):750-5. PubMed ID: 16595817
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.